Jazz Pharmaceuticals posts $215 million in net income for third quarter

Green Market Report
By John SchroyerNov 7, 2024, 1:26 pm64 pts
Ireland-based Jazz Pharmaceuticals (Nasdaq: JAZZ), the makers of Epidiolex, reported net income in the third quarter this year of $215 million, with revenue up 9% year-over-year. That brings the company’s total net income for the year so far to $369 million on revenue of $2.9 billion. The company’s…

Read Article Share
Share Article
- email
- twitter
- facebook
- pocket
- reddit
- tumblr
- linkedin
- pinterest

Trending Today on NewsBudz

Hybridization: The life and legacy of cannabis strains 69

AGLC launches Forget Bad Bud campaign 66

United Kingdom should raise THC allowed in hemp, panel recommends 65

Turning Point Brands raises outlook on Zig-Zag, nicotine growth 65

Jazz Pharmaceuticals posts $215 million in net income for third quarter 64

Curaleaf secures US$40M credit line after stock plummets 64

Puff ‘N’ Pitch Holding Cannabis Networking Party 63

Marijuana social equity transporters in Illinois file civil rights complaint 63

About NewsBudz

NewsBudz is a marijuana and medical cannabis news app. The site delivers a daily feed of the latest cannabis news. We aggregate over 30 of the web's best sources for news about marijuana, hemp and legalization to keep you informed.

Stay on top of the latest news headlines, trends and developments worldwide around recreational and medical marijuana. Sit back and relax, while you read learn and share. On the web or your mobile device, NewsBudz is your cannabis news stream.